Bile acids (BAs) have been studied as potential biomarkers of drug-induced liver injury. However, the relationship between levels of individual BAs and specific forms of liver injury remains to be fully understood. Thus, we set out to evaluate cholic acid (CA), glycocholic acid (GCA), and taurocholic acid (TCA) as potential biomarkers of liver injury in rodent toxicity studies. 
Adverse drug reactions, especially drug-induced liver injury (DILI), represent a major challenge for drug development. Hepatotoxicity has been considered the most frequent cause of safety-related drug withdrawals for the past 50 years (FDA, 2009; Kola and Landis, 2004; Lazarou et al., 1998; Pirmohamed et al., 2004) . Serum enzymatic activity of alanine aminotransferase (ALT) is considered the gold standard clinical chemistry biomarker of liver injury in preclinical species and humans (Amacher, 2002; Amacher et al., 1998; Ozer et al., 2010) . However, ALT assessments in preclinical studies may present a challenge, especially when increases in ALT activity do not correlate with histopathology findings (Ennulat et al., 2010) . In many cases, these increases can be attributed to induction or extrahepatic injury, such as muscle damage or metabolic state, and might be addressed by additional biochemical parameters. On the other hand, histopathologic analysis may be the only indicator for certain types of liver injury, such as bile duct hyperplasia (BDH). BDH can occur secondary to other abnormalities, such as portal inflammation, cholestasis, and biliary and/or hepatocellular injury, and can also occur as a primary lesion. Thus, the development of additional biomarkers capable of facilitating the interpretation of serum ALT increases and differentiating between various histopathologic findings in preclinical toxicity studies is important.
Efforts to identify and develop additional biomarkers for DILI and/or to enhance the current biomarker panels have been initiated (Amacher et al., 2005; Ozer et al., 2008) . Standard clinical chemistry panels currently include monitoring some combination of ALT, aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) serum activity, as well as serum concentration of total bilirubin (TBIL). However, these often are of limited use for detecting BDH. Several research groups have employed genomics, proteomics, and metabonomics platforms in hopes of identifying potential biomarkers in this area. Recent attention has been given to bile acids (BAs), which have been identified in several metabonomic studies. These studies indicated that an altered BA profile was a key characteristic of the toxic response in the liver (Beckwith-Hall et al., 1998; Davis and Thompson, 1993; Lin et al., 2009; Yamazaki et al., 2013) .
BAs are a class of structurally similar compounds that play essential roles in cholesterol homeostasis, lipid absorption, and intestinal signaling (Xiang et al., 2010) . Synthesized in the liver from cholesterol, BAs are excreted into the small intestine via the bile duct mainly as glycine or taurine conjugates and then Animals. All studies were approved and conducted under the oversight of the Institutional Animal Care and Use Committee. Studies were conducted on male Sprague Dawley rats (approximately 6-9 weeks old) or male CD-1 mice (approximately 6-8 weeks old), with the exception of the ISO study that used Hanover Wistar rats (approximately 6-9 weeks old). Hanover Wistar was selected for the ISO study because we had conducted full characterization of the cardiac toxicity in this strain, and no differences in serum concentrations of individual BAs have been observed between the 2 strains of rats (data not published). Drinking water and a standard commercial laboratory certified rodent diet were provided ad libitum throughout the studies. All rats were in the fasted state prior to necropsy.
General study design. Test articles (N = 9) were selected to induce liver injury or injury to other organs. These compounds included classic hepatotoxicants, a cardiac toxicant, a testicular toxicant, a compound known to elicit BDH, and a nontoxic comparator compound. Within each study, a vehicle control group was utilized with the same number of animals as treatment groups. Treatments of test article or vehicle were administrated to rats or mice for a period of time by oral (PO) gavage or subcutaneous (SC) or intraperitoneal (IP) injection (Table 1 ). Blood samples were collected prior to necropsy at the end of treatment.
Sample collection. Blood samples were collected via the vena cava at necropsy, unless otherwise noted. Serum was collected in tubes containing no anticoagulant and was obtained from all rats dosed with vehicle or compound. Terminal serum samples were collected at the time of necropsy. All serum samples were stored at −80°C until analysis.
Clinical chemistry and histopathology. ALT, AST, ALP, GGT, GLDH, TBIL, and total bile acids (TBAs) were analyzed by standard clinical chemistry techniques on the Siemens Advia 2400 platform. Cerner HNA Millennium Laboratory Information System was used to acquire data.
Histopathologic examination of the liver was performed in all cases with additional evaluation of other major organs when appropriate. Organ samples were fixed in 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin. Liver pathology was generally graded using a 4-point scheme as follows: (1) minimal, (2) mild, (3) moderate, and (4) marked.
Sample preparation for LC/MS/MS analysis. Fifty microliters of each serum sample was placed into an individual well of a Sirocco protein precipitation plate on the top of a 96-well collection plate. Three hundred microliters of methanol was added to each well for protein precipitation. Deuterated standards of CA, GCA, and TCA were used as internal standards (ISs). Ten microliters of the 1.0 µg/ml working solution of IS mixture was added, followed by vortex mixing. After 10 min of centrifugation, the Sirocco plate was removed, the supernatant was evaporated to dryness under a steady stream of N 2 at 37°C. The samples were reconstituted in 50 µl methanol/water (1/1, vol/vol) and then 3 µl was injected onto the LC/MS system. Calibration and quality control standard preparation. One milligram per milliliter of BA stock solutions or IS stock solutions were prepared by dissolving each BA reference in methanol. The individual BA stock solutions were combined and diluted to achieve the concentration of 20 µg/ml for a working standard solution or 1 µg/ml for a working IS solution. Nine calibration standard solutions ranging from 5 to 5000 ng/ml were prepared by serially diluting the working standard solution into charcoal-stripped serum. Quality control (QC) standards were prepared in the same manner at 20, 500, and 4000 ng/ml in stripped serum. The calibration standards and QC standards then went through the sample preparation process described above.
Individual bile acid analysis. Individual bile acid (IBA) analysis was performed by LC/MS/MS. The mass spectrometer was an ABSciex 5500 QTrap equipped with Turbo Spray ion source, operating in negative mode. An Acquity UPLC system was interfaced to the front end of the MS system. All chromatographic separations were performed by gradient elution with an Peak integration and quantification were performed using Analyst 1.5.1 software. Individual standard curves for each BA were constructed by plotting the ratio of the BA peak area to its deuterated standard peak area versus concentration. Slope and y-intercept were calculated using a linear curve fit with 1/x 2 weighting. The concentrations of BAs in study samples were calculated relative to the regression line.
Freshly prepared standard curve and QC samples were included in each analysis run. A run was deemed acceptable if the QC samples were ± 15% of the nominal concentrations and the coefficient of variance (CV) did not exceed 10%.
Method validation. The method was validated using QC samples at 3 concentration levels (20, 200, and 2000 ng/ml) from the calibration curve. Four replicates of each QC sample were analyzed in a single run to determine the intraassay accuracy and precision. This process was repeated 4 times over 4 days in order to determine the interassay accuracy and precision. Accuracy and precision were calculated from the % relative error (RE) [%(measured − theoretical)/theoretical concentration] and relative standard deviation [%RSD = % standard deviation/mean], respectively. The assay recovery was evaluated by comparing the mean detector response of extracted QC samples at low, medium, and high concentrations (20, 200, and 1000 ng/ml) in 4 replicates to those of postextracted serum blanks spiked at equal concentrations. The matrix effect was estimated by comparing the extracted serum residue and the neat solution.
Statistical analysis. Data are presented as individual animals or group mean ± SD. Statistical analyses were conducted by 2-tailed Student's t test to compare drug treatment groups with vehicle control groups. Values significantly different from control are indicated as **p < .01 and *p < .05.
reSuLTS

Development of an LC/MS Assay for Detection of CA, GCA, and TCA
We have developed a sensitive method for the quantification of BAs using LC/MS. Because BAs are endogenous molecules and already present in rodent serum, we used charcoal-stripped rat serum for the standard curve and QC sample preparations. To increase the method accuracy and precision, deuterium-labeled ISs for each corresponding BA were used for the quantification. The accuracy and precision of TCA have been reported to be acceptable only when d 4 -TCA was used as the IS (Xiang et al., 2010) . All BAs gave excellent linear response over a 10 3 dynamic range of 5-5000 ng/ml, with coefficients of determination (R 2 ) above 0.999. The lower detection limit for these BAs was 0.5 ng/ml. Mean intraassay accuracy was 95%-109% for the 3 IBAs, with a mean CV of 3%-8%; mean interassay accuracy was 97%-106%, with a mean CV of 4%-10% (Table 2) . The mean recovery rates of the extraction procedures were between 103% and 105%. No significant matrix effect was observed, and the signal difference was less than 5%. These values were within the acceptable range, and the method was judged to be suitably accurate and precise for the analytes.
Currently, no published data can be found on the reference ranges of individual serum BA levels. The 3 IBA serum concentrations from various vehicle-treated rodents in toxicology studies were generated here to provide baseline endogenous levels. Endogenous levels of TCA, GCA, and CA in various vehicle-treated rats (n = 46) measured by this LC/MS assay were 0.184 ± 0.153 µg/ml, 0.559 ± 0.333 µg/ml, and 5.455 ± 2.196 µg/ ml, respectively; the serum levels of TCA, GCA, and CA in various vehicle-treated mice (n = 18) were 0.470 ± 0.464 µg/ ml, 0.004 ± 0.002 µg/ml, and 0.091 ± 0.11 µg/ml, respectively.
Serum BA Profiles After Treatment With Model Liver Toxicants
As expected, the treatment of rats with model liver toxicants GalN, MC, ANIT, and APAP caused a wide degree of hepatocellular/hepatobiliary effects detected via histopathology and serum biochemical analyses (Table 3) . As expected, no histopathologic or serum biomarker changes were observed in vehicle-treated animals.
Rats dosed with a single dose of 1000 mg/kg GalN for 24 h revealed moderate to marked panlobular hepatocellular necrosis that was randomly distributed throughout the liver (Fig. 1A) . Statistically significant, treatment-related increases in serum ALT, AST, and GLDH activity levels, together with increased concentrations of total BAs, were also noted. The LC/MS analysis of CA, GCA, and TCA levels from the GaIN-treated rats showed statistically significant elevations of serum concentrations for all measured BAs. CA, as one of the primary BAs in rats, remained the most abundant BA in GalN-treated animals (Fig. 2) . Interestingly, the BA proportions changed after treatment with GalN with CA accounting for 51% of the total 3 BAs measured as compared with 93% in the control group. Conversely, TCA accounted for 41% of the total 3 BAs in the profile after treatment compared with 2% in controls.
Rats dosed with a single dose of 1000 mg/kg APAP for 24 h produced characteristic hepatocellular necrosis that was accompanied by significant increases in ALT, AST, ALP, and GLDH activity and elevation of total BA concentrations (Fig. 1B) . No other clinical chemistry parameters, such as GGT and TBIL, exhibited significant changes. LC/MS analysis revealed statistically significant changes in serum concentrations of the 3 IBAs when compared with their corresponding control groups (Table 3) . APAP treatment resulted in an IBA profile similar to GalN treatment with CA remaining the major BA (77% of the total 3 BAs) as shown in Figure 2 .
Treatment of rats with 30 or 100 mg/kg of ANIT for 24 h caused mild to moderate hepatobiliary portal inflammation and biliary degeneration and necrosis in most animals ( Fig. 1C) . These changes were slightly more extensive in rats given 100 mg/kg of ANIT, as compared with rats given 30 mg/ kg. Focal or multifocal, minimal, randomly scattered areas of hepatocellular necrosis were observed in some rats given each dose. The biomarker analysis showed statistical increases in levels of all tested biomarkers (ALT, AST, ALP, GLDH, GGT, TBIL, and total BAs) at both dose levels. The LC/MS analysis of CA, GCA, and TCA concentrations in ANIT-treated rats revealed statistically significant elevations. Furthermore, the proportions of the 3 IBAs were altered markedly. Conjugated BAs, especially TCA, were substantially elevated in both the 30 and 100 mg/kg groups (682× and 856× fold increases over the control group) and became the predominate BA in the treated groups. The unconjugated BA (CA) exhibited a comparatively small, yet statistically significant increase (Fig. 2) . The ratio of the taurine conjugate over the total 3 BAs was higher in the 100 mg/kg group as compared with the 30 mg/kg group (data not shown). Paradoxically, ALT, AST, and GLDH had larger fold changes in the 30 mg/kg dose group (4.1×, 5.7×, and 64× control, respectively) than in the 100 mg/kg group (1.9×, 3.4×, and 35× control, respectively). The fold increases of ALP, GGT, and TBIL, which are generally considered indicators of hepatobiliary toxicity, were slightly increased in the 100 mg/kg group as compared with the 30 mg/kg group. This was consistent with TCA levels, the predominant BA here, which showed dose-dependent increases from 30 to 100 mg/kg (Table 3) . Treatment of rats with a single dose of 0.2 mg/kg MC for 24 h caused moderate to marked centrilobular necrosis with frequent involvement of adjacent portal tracts, which include biliary tracts. These findings were accompanied by significantly increased activity levels for ALT, AST, GLDH, ALP, TBIL, and total BAs (Fig. 1D) . The LC/MS analysis of CA, GCA, and TCA levels from the rats treated with MC showed statistically significant elevations of serum concentrations of all measured BAs. Again, the BA proportions changed dramatically. TCA had the largest fold increases of 903× over the control (Table 3) and became the major BA accounting for 58% of the total 3 BAs compared with 1.4% in control (Fig. 2) .
Serum BA Profiles and BDH
To evaluate the BA profile in response to BDH, we treated rats with a well-characterized drug candidate (compound A) that was discontinued from development due to prevalent BDH detected in rat safety studies. To assess specificity of the biomarker response, we used a structurally similar discontinued drug candidate of the same class (compound B) that did not cause BDH in rat safety studies. As expected, histopathologic examination of rats dosed with compound A revealed mild to moderate BDH in the 3 highest dose groups, 300, 500, and 1000 mg/kg (Fig. 1E ). In agreement with previous studies, the classical biomarkers of liver injury measured in our studies (ALT, AST, ALP, GLDH, GGT, TBIL, and TBAs) failed to detect BDH. Although total BA levels detected by an enzyme cycling-based assay was unchanged, the LC/MS analysis of At the 6-h time point changes in the heart consisted predominantly of minimal to mild subepicardial hemorrhage/edema at all dose levels; by 24 h, this progressed to also include minimal to mild myocardial degeneration/necrosis and inflammation at all dose levels.
d
Minimal mesenteric lipid depletion in the 500 mg/kg group; moderate to marked zymogen decrease in pancreas and mesenteric lipid depletion in the 500 mg/kg group.
e Minimal epidydimal spermatic granulomas in the 75 mg/kg group with mild epidydimal interstitial inflammation and skeletal muscle inflammation in the 150 mg/kg group. Statistically significant changes are indicated by *p < .05, **p < .01. 
Evaluation of SErum BilE acid ProfilES
CA, GCA, and TCA revealed statistically significant increases of the conjugated BAs, GCA, and TCA, correlating with the BDH findings (Fig. 2) . No statistically significant changes were observed for CA concentrations in any dose group, regardless of the presence or absence of BDH (Table 3) . None of IBAs significantly changed in the groups that had no histopathological findings. As expected, the treatment of rats with compound B did not affect any biomarkers measured in our studies, and no histopathology findings were observed in the liver (Supplementary Data). Due to the limited tolerability of compound B in rats, animals could not be dosed above 300 mg/ kg (Table 3) .
A similar study was conducted in mice to investigate the translation of biliary hyperplasia from rats to mice with compound A.
Moderate to marked portal tract inflammation with associated bile duct degeneration and hyperplasia was observed in the 2 groups treated with compound A. Some mice exhibited poor tolerance at the high dose of 1000 mg/kg, so those samples were not analyzed. TCA and GCA again were significantly increased in the compound A-treated groups (Fig. 3) . No significant changes were observed for CA in the treated groups compared with the concurrent control group. Even though mice and rats exhibit different profiles for the 3 BAs (TCA is the predominate BA in mice instead of CA in rats.), these results in mice mimicked those in the rat studies in that increases in conjugated BAs were observed in animals with BDH and no changes were observed in other parameters, providing confidence in the potential use of individual BAs as biomarkers of BDH. FiG. 1 . Histopathology analysis. Representative hematoxylin and eosin stained sections of liver from rats treated with 1000 mg/kg of galactosamine (A); 1000 mg/kg of acetaminophen (B); 100 mg/kg of α-naphthylisothiocyanate (C); 0.2 mg/kg of microcystin (D); 1000 mg/kg of compound A (E); or 4000 μg/kg of isoproterenol (F). The isoproterenol image is representative of all those without any liver findings (compound B, compound C, and compound D). All images taken using ×400 magnification.
Serum BA Profile After Treatment With Model Nonhepatic Toxicants
To evaluate whether or not the changes in individual BAs are specific to liver injury, we analyzed serum samples from studies with model nonhepatic toxicants (Table 1) . ISO is known to induce cardiac damage at certain dosages (York et al., 2007; Zhang et al., 2008) . In the ISO study, male Hanover Wistar rats received a single dose of 100, 500, or 4000 µg/kg of ISO SC. As expected, the ISO-treated rats exhibited a minimal to mild subepicardial hemorrhage/edema at all dose levels, accompanied by increases in AST activities in the 500 and 4000 µg/kg dose groups at the 6-h time point after treatment. At the later 24-h time point after ISO treatment, the rats showed cardiac toxicity characterized by myocardial inflammation and necrosis, without significant changes in clinical chemistry biomarkers (Table 3 ). The livers of ISO-treated rats had no histopathological findings at both the 6-and 24-h time points (Fig. 1F) and no statistically significant changes in serum levels of CA, GCA, or TCA (Fig. 2) . A statistically significant increase of total BAs was noted in animals treated with 500 µg/ml of ISO at 6 h postdose, but was not dose or time dependent (Table 3) . The fact that the levels of individual BAs in vehicle-treated rats FiG. 2 . Effects of various compounds on levels of serum IBAs in rats measured by LC/MS/MS. Each bar represents the mean ± SD for 4-10 rats as described in Table 1 . Statistical analysis was performed by 2-tailed Student's t test. Abbreviations: ANIT, α-naphthylisothiocyanate; CA, cholic acid; GalN, galactosamine; GCA, glycocholic acid; IBA, individual bile acid; ISO, isoproterenol; MC, microcystin, TCA, taurocholic acid.
in the ISO study did not differ from those of vehicle-treated Sprague Dawley rats in the other studies (Fig. 2) , indicates the absence of strain-specific differences for serum concentrations of individual BAs between the Hanover Wistar and Sprague Dawley rats.
Compounds C and D are discontinued drug candidates with well-characterized, nonhepatotoxic findings. Compound C caused decreases in body weight and reductions in food consumption, as well as effects associated with the expected pharmacology of this compound, including lipid depletion of mesenteric fat that ranged from minimal at 50 mg/kg to moderate or marked at 500 mg/kg, and decreased pancreatic zymogen granules ranging from minimal to mild at 50 and 500 mg/kg. Compound D caused moderate to marked epididymal toxicity. With the exception of decreases in GCA for animals in the high-dose group of compound D, none of the 3 individual BAs exhibited statistically significant increases in their serum levels for animals treated with compound C or D (Table 3 ). The biological meaning of the decreases observed in GCA with the high dose of compound D is unknown at this time, and further experimentation is needed to understand this observation. Because of sample size limitations, we could not analyze GLDH and total BAs. Although we observed small increases in ALT and AST in compound C-treated animals, and in ALT and ALP in compound D-treated animals (Table 3) , their livers were microscopically normal (Supplementary Data).
DiSCuSSion
DILI is the single greatest cause for the termination of drug development candidates and for the withdrawal of approved drugs from the market (Kaplowitz, 2005; Nathwani et al., 2005) . A well-characterized panel of standard biomarkers that includes ALT, AST, GLDH, ALP, TBIL, and GGT is used for monitoring liver injury in preclinical species and clinical practice (Antoine et al., 2009; EMEA, 2010) . Nevertheless, more specific biomarkers capable of distinguishing various components of liver injury, such as hepatocellular and hepatobiliary damage, are needed for assessing the risk of liver injury to humans during drug development (Bailey et al., 2012) . Recently, individual BAs, such as CA, GCA, and TCA, and/ or BA profiling have been proposed as potential biomarkers of DILI in preclinical and clinical studies (Tribe et al., 2010; Trottier et al., 2011; Yamazaki et al., 2013) . In this study, we set out to evaluate the performance of CA, GCA, and TCA as potential biomarkers of DILI in rodents by comparing them with standard biomarkers of liver injury in rats and mice treated with model hepatotoxicants that cause hepatocellular and/or hepatobiliary damage.
We have developed a rapid, quantitative LC/MS assay for the detection of BAs. This assay provided high sensitivity and specificity to simultaneously measure 3 serum BAs in a short run time using a single-step sample preparation. This method was validated to ensure high accuracy and precision, and therefore the reliability of its results as applied to toxicology studies in rodents. The predominant BA in rats was CA, followed by GCA at 10-fold lower level than CA. TCA was observed to be 3-fold lower than GCA. On the other hand, the BA levels in mice were 10-to 100-fold lower than in rats with TCA being predominant followed by CA and GCA. In humans, the levels of glycine conjugates have been reported as being higher than the unconjugated forms, and taurine conjugates reported as approximately 3-fold lower than the free forms (Trottier et al., 2011) . These species-specific differences are in line with published reports (Alnouti et al., 2008; Ando et al., 2006; Shimada et al., 2010) and likely due to species-specific variation in BA biosynthesis and metabolism.
Treatment of rats with model hepatotoxicants GaIN, MC, ANIT, and APAP resulted in characteristic histopathologic signs of liver injury. A wide degree of hepatocellular and/ or hepatobiliary effects were detected via histopathology. The liver injury correlated with significant increases in serum levels of standard biomarkers of liver injury, including total BAs measured using the total BA enzyme assay (Advia 2400). As expected, the serum levels of CA, GCA, and TCA were also significantly increased. The biomarker response showed a high degree of specificity because none of the rats treated with vehicle or nonhepatic toxicants (ISO, compounds C and D) showed treatment-related increases in biomarker response. These results are in accord with published findings (Wang and Stacey, 1990; Want et al., 2010; Yamazaki et al., 2013) . For example, Yamazaki et al. (2013) observed increases in plasma levels of TCA and GCA, as well as increases in urine CA levels, upon dosing rats with APAP and ANIT. Levels of TCA were found to remain unchanged or decreased in APAP-treated animals at a later time point, yet these animals did not exhibit the expected APAP-induced necrosis. These results further confirm our observations. In contrast to model hepatotoxicants, compound A induced BDH in the absence of hepatocellular damage, and the severity of injury correlated with increasing dose. Treatment of rats with compound A did not change levels of the standard biomarkers of liver injury, including total BAs. However, a dosedependent increase of conjugated BAs GCA and TCA was observed. Interestingly, the levels of unconjugated CA remained unchanged. These changes in both GCA and TCA were not observed with a structurally related compound, compound B, that was devoid of any liver pathology and did not exhibit any changes in any of the other endpoints measured. Compounds that induce primary BDH are rare, yet the concern is how this form of injury translates into the clinic, which is currently unknown. In addition, BDH preclinical findings can be accompanied by other forms of liver injury or other toxicities, making it difficult to discriminate any response in the serum. The fact that similar increase of conjugated BAs GCA and TCA in the absence of changes in unconjugated CA was found in mice treated with compound A (Fig. 3) suggested applicability of the BA profile as a biomarker of BDH in rodents. Furthermore, our data indicated the superior specificity of CA, GCA, and TCA as biomarkers of liver injury when compared with standard biomarkers, such as ALT. In contrast, the total BA assay was not useful for detection of BDH indicating the need for assessment of individual BAs and BA profiles. These results are significant because they are the first to indicate that serum TCA and GCA are useful tools for detecting BDH in rodents, in the absence of changes of any other biomarkers.
Close examination of BA profiles, in particular the evaluation of relative proportion of conjugated and unconjugated BAs, across the compound set revealed that hepatocellular damage was associated with predominant elevation of unconjugated CA, whereas hepatobiliary hyperplasia was associated with predominant increase of conjugated BAs GCA and TCA (Fig. 2) . For instance, APAP treatment that produced hepatocellular damage increased mainly CA, whereas compound A that produced BDH increased levels of GCA and TCA exclusively. This suggested that a BA profile characterized by prominent increases in CA may be a potential marker for hepatocyte damage, whereas a profile marked by increases in TCA and GCA may serve as an indicator of biliary injury. Because in many instances, both hepatocellular and hepatobiliary damage occur together, one could see a continuum of changes in our data. Such as, in the MC study, histopathology revealed extensive hepatocellular necrosis that spilled over into and involved biliary regions as well, and the LC/MS/ MS analysis demonstrated a significantly altered serum BA profile with TCA being the predominant BA. In the case of ANIT, massive fold increases of the conjugated BAs indicated severe biliary injury, whereas the mild fold increases of CA also indicated less intensive hepatocellular injury. The different intensities of fold increases in conjugated and unconjugated BAs may indicate a different site or severity of hepatic injury. As summarized in Table 4 , the increased CA fold changes correlated well with hepatocellular injury/necrosis across the compound set. Our findings supported the publication from InnoMed PredTox Consortium regarding the pathogenesis of liver injury (Ellinger-Ziegelbauer et al., 2011) , which proposed that hepatocyte damage may have interfered with BA metabolism and/or conjugation, leading to accumulation of toxic unconjugated BAs in hepatocytes and subsequent leakage into serum, whereas the biliary toxicity may have arisen from impaired transport of conjugated BAs across the canalicular membrane of hepatocytes or leakage as a result of bile duct injury. Our observations were also in accord with the publications from Trottier et al. (2011) and Meng et al. (1997) . Taken together with our findings, these studies indicate that the 3 BA proportions/profiles themselves are significant, and these profiles are likely to be specific to the site of damage and provide insight into the mechanisms involved in different types of liver toxicity. Our data suggested both serum BA levels and serum BA patterns can be sensitive indicators of hepatic damage, and patterns in IBAs may be established for differentiating various types of liver injury and findings, such as BDH, cholestasis, necrosis, steatosis, and adaptive responses. For example, in the publication by Yamazaki et al. (2013) , the compounds that induced steatosis had significant increases in the tauro-conjugated BAs, without increases in any other BAs measured, suggesting a different profile for steatosis than we observed for necrosis or BDH.
Currently, modest ALT elevations may necessitate placing a hold upon clinical development of a compound. If these elevations were better understood through newly developed biomarker tools, the drug development process could progress Evaluation of SErum BilE acid ProfilES faster with more confidence in safety to bring needed medicines to market. At this point, none of the new biomarkers have the potential to be the universal safety parameter for liver in isolation. Instead, a combination of conventional endpoints and newly developed markers may provide a panel showing adequate sensitivity and specificity for most preclinical and clinical contexts of relevance. Biomarkers, such as troponin, myosin light chain, and fatty acid-binding protein, provide data regarding skeletal muscle and cardiac injury, which can also induce elevations in ALT. Individual BAs and markers such as these could be run concurrently with ALT for better interpretation of ALT elevation in preclinical toxicology studies. Based on this fast and accurate LC/MS/MS method, the assessment of these 3 individual BAs could add information to the assessment of liver toxicity during compound development. Although more data are needed, our study indicated hepatotoxicants differentially affect circulating BAs, resulting in different BA profiles. Particularly, the specific correlation of CA to hepatocellular necrosis and the correlation of GCA and TCA without changes in CA to BDH could provide mechanistic insight for a specific toxicity. Additional compounds need to be tested to verify if this pattern holds true, and additional BAs, such as CDCA, could be evaluated to determine if they could add specificity to these findings. In the clinic, Burkard et al. (2005) reported that conjugated BAs were elevated in serum from patients with liver disease by differentiated quantification of human individual BAs in serum samples. Alternations in the BA profile and shifts in BA synthesis have been reported in various human hepatic disease states, such as primary biliary cirrhosis, chronic hepatitis C, and nonalcoholic fatty liver diseases (Crosignani et al., 2007; Lake et al., 2013) . Therefore, the individual BAs as potential biomarkers might be translatable to clinical practice and may further be used as personalized medicine biomarkers by monitoring an individual's serum BA profiles (Shimada et al., 2010) .
In conclusion, our data suggest the potential for relationships to be established between IBAs and specific liver toxicity findings. Incorporation of serum individual BA analysis may enhance conventional safety assessment in preclinical drug development studies, and BA profiles could be particularly valuable in situations where traditional clinical chemistry measurements are ambiguous, such as BDH. Further studies in preclinical models, including nonhuman primates, will allow better understanding of the relationship between IBAs and DILI.
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